Haematopoietic stem cell therapy (Novartis/Regenerex)

N/A

Report date: 2023/10/13 20:08:36

Base Information

Drug NameHaematopoietic stem cell therapy (Novartis/Regenerex)
Drug Alias NameFCRxFacilitating Cell TherapyFCR-001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCell replacementsImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsRejection of organ transplantationScleroderma, DiffuseRenal Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegenerex Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunoFree IncRegenerex LlcTalaris Therapeutics Inc +[4] 
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationScleroderma, DiffuseRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A